In this study, we built on our previous findings showing that both Aurora kinase A and PLK1 are hyper-activated in an imatinib-resistant CML K562 (K562R) cell line (16). Here, AURKA is linked to chronic myelogenous leukemia, BCR-ABL1 positive.